Financial PerformanceBluebird was reaching the end of its cash runway, unlikely to achieve near-term profitability from its ongoing commercial launches, and at risk of defaulting on its loan covenants.
Revenue Decline3Q24 revenue of $10.6mm was below the expected $21.1mm and continues to decline sequentially QoQ from $16.1mm in 2Q24 and $18.6mm in 1Q24.
Sales EstimatesSales estimates for Lyfgenia are reduced due to slower-than-expected uptake in sickle-cell disease.